Directed new share issue in Vicore Pharma Holding AB (SE) — SEK 200 million

Carnegie acted as joint bookrunner in the directed new share issue of 10,000,000 shares at a subscription price of SEK 20.0 per share. Vicore is a clinical-stage pharmaceutical company focused on developing innovative medicines in severe diseases where the Angiotensin II type 2 receptor (AT2R) plays an important role.
December 2022.